Molecular Partners (MOLN) to Release Quarterly Earnings on Thursday

Molecular Partners (NASDAQ:MOLN) is projected to post its Q4 2025 results before the market opens on Thursday, March 5th. Analysts expect Molecular Partners to post earnings of ($0.38) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Friday, March 13, 2026 at 8:00 AM ET.

Molecular Partners Price Performance

Shares of NASDAQ:MOLN opened at $5.05 on Thursday. Molecular Partners has a 1 year low of $3.36 and a 1 year high of $5.11. The company has a market capitalization of $203.92 million, a PE ratio of -2.63 and a beta of 1.07. The business has a fifty day moving average price of $4.42 and a two-hundred day moving average price of $4.08.

Analyst Ratings Changes

Several research firms recently weighed in on MOLN. HC Wainwright began coverage on shares of Molecular Partners in a research report on Tuesday, January 27th. They set a “buy” rating and a $13.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Molecular Partners in a research note on Monday, December 22nd. Finally, JPMorgan Chase & Co. decreased their price target on shares of Molecular Partners from $4.00 to $3.75 and set a “neutral” rating for the company in a research note on Monday, December 8th. Two analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $9.58.

Institutional Trading of Molecular Partners

An institutional investor recently bought a new position in Molecular Partners stock. SmartHarvest Portfolios LLC bought a new position in Molecular Partners AG Sponsored ADR (NASDAQ:MOLN) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 12,311 shares of the company’s stock, valued at approximately $54,000. 26.55% of the stock is currently owned by institutional investors.

About Molecular Partners

Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Zurich, Switzerland, specializing in the design and development of DARPin® (Designed Ankyrin Repeat Protein) therapies. These small, modular proteins are engineered to bind with high specificity and affinity to disease-relevant targets. The company’s technology platform aims to deliver novel treatments across multiple therapeutic areas by leveraging the unique properties of DARPins, including stability, tissue penetration and multi-specific binding capabilities.

The company’s development pipeline spans infectious diseases, ophthalmology and oncology.